Cyclacel Pharma Financials
Cyclacel Pharma (CYCC) reported $747K in revenue for fiscal year 2025, up 1637.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing support remains central as positive reported earnings coexist with operating cash outflows and a recently reset balance sheet.
Across FY2023-FY2025, net income was positive while operating cash flow remained negative, meaning the reported earnings stream did not translate into cash from operations. In FY2025, a4.0% net margin sat beside a-11.3% operating margin, pointing to non-operating items rather than core operations as the source of reported profit.
The balance-sheet reset was material: total liabilities fell to
Development spending dropped from
Financial Health Signals
Cyclacel Pharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cyclacel Pharma scores -73.94, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.3M) relative to total liabilities ($1.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cyclacel Pharma passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cyclacel Pharma used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Cyclacel Pharma reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cyclacel Pharma generated $747K in revenue in fiscal year 2025. This represents an increase of 1637.2% from the prior year.
Cyclacel Pharma's EBITDA was -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.8% from the prior year.
Cyclacel Pharma reported $3.0M in net income in fiscal year 2025. This represents a decrease of 73.3% from the prior year.
Cyclacel Pharma earned -$6.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.7% from the prior year.
Cash & Balance Sheet
Cyclacel Pharma held $3.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cyclacel Pharma's ROE was 43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cyclacel Pharma invested $848K in research and development in fiscal year 2025. This represents a decrease of 87.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CYCC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $743K | N/A | $81K | N/A | N/A | $0-100.0% | $10K+150.0% | $4K |
| R&D Expenses | N/A | N/A | $5K-92.6% | $68K-91.7% | $822K-6.6% | $880K-7.4% | $950K-53.0% | $2.0M |
| SG&A Expenses | $389K | N/A | $1.0M-19.6% | $1.2M-70.4% | $4.2M+344.5% | $948K-23.4% | $1.2M-23.9% | $1.6M |
| Operating Income | -$246K | N/A | -$992K+24.7% | -$1.3M+68.7% | -$4.2M-130.5% | -$1.8M+16.0% | -$2.2M+40.3% | -$3.6M |
| Interest Expense | $9K | N/A | $9K+350.0% | $2K-66.7% | $6K-80.0% | $30K+275.0% | $8K+128.6% | -$28K |
| Income Tax | $30K | N/A | N/A | $2K | N/A | $1.2M+668.6% | -$210K+49.0% | -$412K |
| Net Income | -$197K | N/A | -$988K+25.0% | -$1.3M-1527.2% | -$81K-100.4% | $19.4M+1089.9% | -$2.0M+39.9% | -$3.3M |
| EPS (Diluted) | -$0.04 | N/A | -$1.31 | -$0.98 | $0.00 | N/A | -$43.80 | -$172.18 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CYCC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M-7.6% | $8.2M+0.3% | $8.2M+85.4% | $4.4M+17.9% | $3.7M-8.8% | $4.1M-23.9% | $5.4M-34.3% | $8.2M |
| Current Assets | $5.6M-10.1% | $6.3M-2.9% | $6.4M+47.0% | $4.4M+18.0% | $3.7M+1.1% | $3.7M-25.2% | $4.9M-36.3% | $7.7M |
| Cash & Equivalents | $3.3M-4.7% | $3.5M-8.7% | $3.8M-10.2% | $4.3M+23.9% | $3.5M+10.0% | $3.1M+5.2% | $3.0M-50.3% | $6.0M |
| Inventory | $947K-31.6% | $1.4M+1.2% | $1.4M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.2M-5.5% | $1.3M+73.4% | $725K | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.6M0.0% | $1.6M0.0% | $1.6M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $804K-40.1% | $1.3M+26.5% | $1.1M+37.9% | $770K+14.6% | $672K-89.3% | $6.3M-1.3% | $6.4M-11.7% | $7.2M |
| Current Liabilities | $796K-40.2% | $1.3M+32.9% | $1.0M+31.8% | $760K+14.6% | $663K-89.4% | $6.3M-1.3% | $6.4M-11.6% | $7.2M |
| Total Equity | $6.8M-1.2% | $6.8M-3.6% | $7.1M+95.4% | $3.6M+18.6% | $3.1M+240.8% | -$2.2M-124.1% | -$970K-197.1% | $999K |
| Retained Earnings | -$454.6M0.0% | -$454.4M-2.3% | -$444.3M-0.6% | -$441.8M-0.3% | -$440.5M-0.2% | -$439.5M-0.7% | -$436.4M-0.5% | -$434.5M |
Not reported in any period shown, so not listed: Long-Term Debt.
CYCC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$278K-742.4% | -$33K+92.4% | -$434K+58.9% | -$1.1M+67.5% | -$3.2M-139.5% | -$1.4M+55.8% | -$3.1M+0.6% | -$3.1M |
| Capital Expenditures | $1K | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | -$279K | N/A | N/A | N/A | N/A | N/A | -$3.1M | N/A |
| Investing Cash Flow | -$1K | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Financing Cash Flow | $105K+140.5% | -$259K-8533.3% | -$3K-100.2% | $1.9M-48.4% | $3.6M+126.0% | $1.6M+161400.0% | -$1K-100.0% | $6.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CYCC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -33.1% | N/A | -1224.7% | N/A | N/A | N/A | -21770.0% | -91100.0% |
| Net Margin | -26.5% | N/A | -1219.8% | N/A | N/A | N/A | -19570.0% | -81425.0% |
| Return on Equity | -2.9% | N/A | -13.9%+22.4pp | -36.3%-33.6pp | -2.6% | N/A | N/A | -326.0% |
| Return on Assets | -2.6% | N/A | -12.1%+17.8pp | -29.9%-27.8pp | -2.2%-475.3pp | 473.2%+509.5pp | -36.4%+3.4pp | -39.8% |
| Current Ratio | 7.06+2.4x | 4.70-1.7x | 6.43+0.7x | 5.77+0.2x | 5.60+5.0x | 0.59-0.2x | 0.77-0.3x | 1.07 |
| Debt-to-Equity | 0.12-0.1x | 0.200.0x | 0.15-0.1x | 0.210.0x | 0.22 | N/A | N/A | 7.20 |
| FCF Margin | -37.5% | N/A | N/A | N/A | N/A | N/A | -30670.0% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cyclacel Pharma Ranks
Frequently Asked Questions
What is Cyclacel Pharma's annual revenue?
Cyclacel Pharma (CYCC) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cyclacel Pharma's revenue growing?
Cyclacel Pharma (CYCC) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Is Cyclacel Pharma profitable?
Yes, Cyclacel Pharma (CYCC) reported a net income of $3.0M in fiscal year 2025.
What is Cyclacel Pharma's EBITDA?
Cyclacel Pharma (CYCC) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cyclacel Pharma's return on equity (ROE)?
Cyclacel Pharma (CYCC) has a return on equity of 43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cyclacel Pharma's operating cash flow?
Cyclacel Pharma (CYCC) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cyclacel Pharma's total assets?
Cyclacel Pharma (CYCC) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Cyclacel Pharma spend on research and development?
Cyclacel Pharma (CYCC) invested $848K in research and development during fiscal year 2025.
What is Cyclacel Pharma's current ratio?
Cyclacel Pharma (CYCC) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
What is Cyclacel Pharma's debt-to-equity ratio?
Cyclacel Pharma (CYCC) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cyclacel Pharma's return on assets (ROA)?
Cyclacel Pharma (CYCC) had a return on assets of 36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cyclacel Pharma's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cyclacel Pharma (CYCC) held $3.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cyclacel Pharma's Altman Z-Score?
Cyclacel Pharma (CYCC) has an Altman Z-Score of -73.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cyclacel Pharma's Piotroski F-Score?
Cyclacel Pharma (CYCC) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cyclacel Pharma's earnings high quality?
For every $1 of reported earnings, Cyclacel Pharma (CYCC) used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cyclacel Pharma cover its interest payments?
Cyclacel Pharma (CYCC) reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.